TIDMIMM
RNS Number : 1084J
Immupharma PLC
11 August 2023
11 August 2023
ImmuPharma PLC
("ImmuPharma" or the "Company")
BOARD STRENGTHENED AHEAD OF NEXT PHASE OF COMPANY
PROGRESSION
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and
development company, provides notification of changes to its Board
of Directors.
It has been a pivotal 2023 for ImmuPharma, specifically within
its P140 autoimmune platform.
Most recently in June, the Company announced that, after
receiving comprehensive guidance from the Food & Drug
Administration ("FDA") on the new Phase 2/3 adaptive clinical trial
protocol for the lead programme for the treatment of patients with
systemic lupus erythematosus ("SLE/Lupus"), it is moving forward
with the study, together with its US partner Avion.
Positive progress on the P140 platform was also announced in May
for a second high medical need disease, chronic idiopathic
demyelinating polyneuropathy ("CIDP"). The Company received
positive feedback from the FDA at a pre-IND meeting for a
late-stage Phase 2/3 adaptive clinical program in patients, which
is a further debilitating auto-immune condition within the
Company's P140 platform.
In parallel with advancements in the late-stage clinical
developments, the Company is also actively in discussions with a
number of potential licensing partners for programmes across the
Company's development portfolio.
In order to align with the new phase of progress, the Company
recognised the need to add further skills and experience to the
Board to ensure that we have the requisite Board composition for
the next stage of evolution of the business.
We are therefore delighted to announce today the appointment of
Dr Laurence Reilly as Senior independent Non-Executive Director and
Chair of the Audit Committee. Dr Reilly brings extensive experience
in managing late-stage clinical programs through to approval, in
addition to commercial and business development experience.
He is currently Vice President of Research & Investments,
working with Royalty Pharma, a New York based life science
investment company focussing on acquisition of biopharmaceutical
royalties and funding of innovation across the biopharmaceutical
industry.
Through his consulting practice (Acumen Life Science Investment
Consulting) Dr Reilly has provided strategic consulting and
due-diligence services to biotech companies, life science venture
capital and private equity clients. He also served as Chief Medical
Officer for Cellectar Biosciences, New Jersey, a late-stage
oncology biotech company. Prior to founding his consulting practice
, Dr Reilly served as Chief Scientific Officer and Vice President
at Avillion, a drug development company focused on the
co-development and financing of drug candidates, where he was
responsible for clinical and strategic oversight of co-development
programs and partnering with both large pharma and biotech,
including Pfizer, Merck KGaA and AstraZeneca. Dr Reilly previously
served as a Clinician - Clinical Development & Medical
Oversight at Pfizer and at Lundbeck as Medical & Scientific
Advisor.
Dr Reilly earned his medical degree from the University of
Liverpool Medical School, U.K., and practiced as Neurosurgery
Resident at Queen Elizabeth University Hospital in Birmingham. Dr
Reilly also holds a Masters Degree in Law from De Montfort
University, U.K.
We are also extremely pleased to welcome Dr Sébastien Goudreau
to the Board.
Dr Goudreau joined ImmuPharma in 2014 as research director and
established the research laboratories of Ureka Pharma (now
ImmuPharma Biotech, the Company's French subsidiary) in Bordeaux,
being promoted in 2021 to Chief Executive Officer of ImmuPharma
Biotech. Notably, working directly with Dr Tim Franklin (ImmuPharma
COO), Dr Goudreau and his team are credited for the development of,
among others, the Company's anti-infective programmes, BioAMB and
BioCin.
Dr Goudreau has also been a key contributor to the progression
of the P140 autoimmune platform including the PK study,
successfully concluded in 2022, and supported the new protocol
design of the Phase 2/3 adaptive clinical studies for both Lupus
and CIDP.
Dr Goudreau obtained his PhD in Chemistry at the Université of
Montréal as a NSERC fellow before moving to Switzerland to conduct
postdoctoral studies at the ETH Zürich as an FRQNT fellow.
At this time, Dr Sanjeev Pandya, has informed the Board that he
wishes to step down from his Non-Executive Director position, in
order to pursue a number of other external opportunities.
All Board changes take place with immediate effect.
Commenting on the Board changes, Tim McCarthy, Chief Executive
Officer said:
"I am delighted to welcome Laurence to the Board. His deep
centred experience of late-stage drug development, together with
his international business development expertise, will perfectly
complement with and support the executive management team and
together will ensure that we have the essential skills and
knowledge required for the next stage of ImmuPharma's
evolution.
I am also extremely pleased to welcome Sébastien to the Board.
Having now worked closely with Sébastien over the last 2 years and
seen first-hand how he has added invaluable insight and clinical
direction within our drug portfolio, his appointment will be an
extremely positive addition to the Board.
We are now on a pivotal course for ImmuPharma. As a Board, we
remain focused on bringing our two key late stage P140 clinical
assets in Lupus and CIDP through their final clinical trials and to
the market.
We also continue to concentrate on further commercial and
partnering opportunities and with these new Board appointments
believe this may be accelerated over the next period. "
End
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
Additional information:
The following information is disclosed pursuant to Schedule Two
paragraph (g) of the AIM Rules for Companies:
Dr Sebastien Goudreau, aged 42, holds or has previously held the
following directorships:
Current directorships and/or Former directorships and/or
partnerships partnerships (within the last
five years):
ImmuPharma France SA* N/A
Ureka Pharma SAS*
FindMolecule Inc.
Pharmanoviq SAS
-------------------------------
*an ImmuPharma group company
Dr Goudreau holds 150,000 shares & 1,150,000 options in the
Company.
Dr Laurence Robert Reilly, aged 41, holds or has previously held
the following directorships:
Current directorships and/or Former directorships and/or
partnerships partnerships (within the last
five years):
HEX Therapeutics LLP N/A
Acumen Life Science Investment
Consulting Limited
-------------------------------
Dr Reilly holds no shares in the Company.
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chief Executive Officer + 44 (0) 207 152 4080
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 36 8 3550
Stanford Capital Partners (Joint Broker)
Patrick Claridge +44 (0) 203 815 8880
John Howes
Bob Pountney
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical
company that discovers and develops peptide-based therapeutics. The
Company's portfolio includes novel peptide therapeutics for
autoimmune diseases and anti-infectives. The lead program, P140
(Lupuzor(TM)), is a first-in class autophagy immunomodulator for
the treatment of Lupus and preclinical analysis suggest therapeutic
activity for many other autoimmune diseases that share the same
autophagy mechanism of action.
For additional information about ImmuPharma please visit
www.immupharma .co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOANKDBKDBKDKFD
(END) Dow Jones Newswires
August 11, 2023 07:04 ET (11:04 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024
